US FDA Officials Offer Tips On How To Improve CMC Packages To Win Generic Approvals
This article was originally published in SRA
Executive Summary
With the US Food and Drug Administration increasingly refusing to receive generic drug applications (also called abbreviated new drug applications or ANDAs) typically because of deficiencies relating to chemistry, manufacturing and controls (CMC), agency officials recently shared some advice on how sponsors can improve their submissions on this front.